After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically.
The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature.
The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment.
Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy.
Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment
Affiliation to a social security scheme
Minor patient
Pregnant patient
Patient under guardianship or conservatorship
Patients who object to the collection of their medical/paramedical data
Single group
molecular analysis
Geneticmolecular analysis on histological blocks
Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.
Refractory patients are defined as any patient progressing through the first therapeutic line of platinum-based chemotherapy. Long responders are defined as any patient who has not progressed within 5 years of the end of platinum salt treatment.
Phenotypic criteria differences between refactory patients and long responder patients
Phenotypic criteria will include BMI, personal history and family history
Clinical criteria differences between refactory patients and long responder patients
Clinical criteria will include age at diagnosis, FIGO stage, initial PCI score, CCO score
Biological criteria difference between refactory patients and long responder patients
Biological criteria include CA-125
Histological criteria differences between refactory patient and long responder patients
Histological criteria include histological type, presence of emboli, Ki-67, RO, RP, WT1, PAX8, PD-L1, CD8, p53, HER2
Click on the lead sponsor to view all of their trials.
